Enveric Biosciences Inc., a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, announced positive results from a preclinical study of its lead drug candidate, EB-003. The study demonstrated that EB-003 significantly decreased context-induced freezing behavior in a well-established rodent model for post-traumatic stress disorder (PTSD) when measured one hour after administration. These results suggest a positive therapeutic effect and rapid fear extinction. EB-003, a neuroplastogen, may enhance hippocampal neuroplasticity without causing hallucinations, potentially improving treatment outcomes for PTSD. Current FDA-approved treatments, such as SSRIs, only result in full remission for 20% to 30% of patients and require several weeks before benefits are observed. The study compared EB-003's effects to those of MDMA, a controlled substance that has shown clinical benefits in PTSD treatment but is not FDA-approved.